Expression of survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological parameters
Expression of survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological parameters
复制标题
DOI：
10.1155/2009/821543
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Jin, Jong-Shiaw
中科院分区：
文献类型：
--
作者：
Lee, Ying-Yu;Yu, Cheng-Ping;Jin, Jong-Shiaw
目的：Survivin和coronin是促进肿瘤进展的因子。我们测试的假设，生存素和coronin的表达相关的临床病理参数的结直肠腺癌和生存time.Methods：生存素和coronin进行了免疫组化分析，使用组织芯片119例标本，从18个良好的，50个中等，27个低分化的结直肠腺癌和24个结直肠腺瘤异型增生。结果：高、中、低分化大肠腺癌组织中Survivin和coronin免疫染色阳性细胞百分率及免疫染色积分均显著高于正常大肠上皮组织。Survivin免疫组化评分与T、M、AJCC/TNM分期显著相关（p < 0.05）。coronin评分与T、M分期显著相关（p < 0.05）。结论：Survivin和coronin的高表达与肿瘤分期和生存期密切相关。Survivin和coronin可能是判断大肠腺癌侵袭性的良好生物标志物。我们的研究结果需要在独立的队列中进行验证，这些数据支持生存素和coronin用于开发新的治疗策略的潜在靶点。
Objective: Survivin and cortactin are factors that promote tumor progression. We tested the hypothesis that survivin and cortactin expressions correlate with the clinico-pathological parameters of colorectal adenocarcinomas and survival time.Methods: Immunohistochemical analysis of survivin and cortactin were performed using tissue microarrays of 119 specimens from 18 well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas and 24 colorectal adenomas with dysplasia. As control, 10 specimens of normal colorectal epithelia were included.Results: The percentage of cells immunostained and the immunostaining scores for survivin and cortactin were all significantly higher in well-, moderately, and poorly differentiated colorectal adenocarcinomas than in normal colorectal epithelia. The survivin immunostaining score was significantly correlated with T, M, and AJCC/TNM stages (p < 0.05). For cortactin, the score was significantly correlated with T and M stages (p < 0.05). Higher survivin immunostaining score was associated with higher mortality.Conclusions: Higher expression of survivin and cortactin correlates significantly with tumor stages and shorter survival time. Survivin and cortactin may be good biomarkers of aggressiveness of colorectal adenocarcinomas. Our findings require validation in independent cohorts and these data support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies.